AIM
MACK

Acrospire Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Acrospire Investment Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-474
Closed -$5K – 2032
2017
Q2 		$5K Buy
+474
New +$9.68K ﹤0.01% 1980

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's MACK Position: Q3 2017 in Review

Acrospire Investment Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 474 shares — an estimated $5K sold.

Acrospire Investment Management first reported a position in MACK in Q2 2017 and held it in 1 quarter. The position peaked at $5K in Q2 2017. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Acrospire Investment Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 474 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $5K.
  • Acrospire Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $5K in Q2 2017.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.